Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 1

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

NCT03247712 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.

Interventions

  • PROCEDURE Surgical Resection
  • DRUG Nivolumab
  • RADIATION Radiation (5 days)
  • RADIATION Radiation (3 days)

Study Locations (1)

Oregon

  • Providence Portland Medical Center — Portland

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-01-15
Est. Completion 2026-12
Phase Phase 1

Sponsor

Providence Health & Services

30 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03247712

The ClinicalTrials.gov registry entry for NCT03247712 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 30 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions — of which Surgical Resection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03247712 reports 1 study location spanning 1 distinct geographic area — top geographies include Oregon. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03247712 about?

NCT03247712 is a clinical study titled "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer". The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.

What is the current status of trial NCT03247712?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-01-15. Estimated completion is 2026-12.

What conditions does trial NCT03247712 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03247712?

The interventions under investigation include: Surgical Resection (PROCEDURE), Nivolumab (DRUG), Radiation (5 days) (RADIATION), Radiation (3 days) (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03247712?

This trial is sponsored by Providence Health & Services, which has 30 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03247712 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial